No Detail Found!

Exploring inflammatory markers: impact on symptom severity and clinical prognosis in diabetic vs. non-diabetic COVID-19 patients

Author(s)
Mehwish Iftikhar Department of Endocrinology, Institute of Endocrinology and Metabolic diseases, Services Institute of Medical Sciences, Lahore, Pakistan
Amna Rizvi Department of Endocrinology, Institute of Endocrinology and Metabolic diseases, Services Institute of Medical Sciences, Lahore, Pakistan
Ghazala Jawwad Depatment of Physiology, Islamic International Medical College, Rawalpindi, Pakistan
Maleha Asim Department of Biochemistry, Islamic International Dental College, Rawalpindi, Pakistan
Aysha Mushtaq Department of Physiology, Hazrat Bari Sarkar Medical & Dental College, Islamabad, Pakistan
Amanat Ali Department of Pharmacology, Hazrat Bari Sarkar Medical & Dental College, Islamabad, Pakistan
Abstract
Objective: To compare inflammatory markers between diabetic and non-diabetic COVID-19 patients, correlating them with symptom severity and clinical outcomes for tailored interventions. Methodology: This multicentric cross-sectional study was conducted from January 2021 to January 2022 and included 610 COVID-19 patients from various hospitals of Rawalpindi, Islamabad, and Lahore. Groups were divided by diabetes status. Data included demographics, symptoms, comorbidities, lab parameters and inflammatory markers. Statistical analyses assessed differences and correlations. Results: Diabetic patients (group I, n=290) had higher comorbidities and severity. Death rate was significantly higher in diabetics (37.6%) compared to non-diabetics (13.8%). Group I exhibited significantly elevated HbA1c, inflammatory markers (TLC, ferritin, d-dimer, C-reactive protein), and lower pH, SPO2. HbA1c correlated negatively with SpO2 (r= -0.272, p<0.001) and positively with total leukocyte count (TLC) (r=0.289, p<0.001), lymphocyte count (r=0.106, p=0.008), ferritin (r=0.129, p<0.001), CRP (r=0.144, p<0.001) and lactate dehydrogenase level (r= 0.096, p<0.001). Regression analysis showed that increase in HbA1c (p<0.001, OR=1.73), lymphocyte (p<0.001, OR=1.71), LDH (p=0.005, OR=1.001), CRP (p<0.001, OR=1.01), d-dimer (p=0.009, OR=1.02) increase the likelihood of mortality and decrease SPO2 (p<0.001, OR=0.85) predict high mortality in COVID-19 patients. Conclusion: Diabetic COVID-19 patients demonstrated worse outcomes and higher inflammatory markers, suggesting a potential link between diabetes, inflammation, and disease severity. correlated negatively with SpO2 (r= -0.272, p<0.001) and positively with total leukocyte count (TLC) (r=0.289, p<0.001), lymphocyte count (r=0.106, p=0.008), ferritin (r=0.129, p<0.001), CRP (r=0.144, p<0.001) and lactate dehydrogenase level (r= 0.096, p<0.001). Regression analysis showed that increase in HbA1c (p<0.001, OR=1.73), lymphocyte (p<0.001, OR=1.71), LDH (p=0.005, OR=1.001), CRP (p<0.001, OR=1.01), d-dimer (p=0.009, OR=1.02) increase the likelihood of mortality and decrease SPO2 (p<0.001, OR=0.85) predict high mortality in COVID-19 patients. Conclusion: Diabetic COVID-19 patients demonstra-ted worse outcomes and higher inflammatory markers, suggesting a potential link between diabetes, inflamma-tion, and disease severity.
Publication Details
Page(s) 295-299
DOI DOI not available
Published Journal: Rawal Medical Journal, Volume: 50, Issue: 2, Year: 2025

Request the full text from PASTIC

Keywords
Ferritin, Diabetes Mellitus, COVID-19, Severity., Covid-19, Inflamma-tory markers
References
Bisen AC,Agrawal S,Sanap SN,Ravi Kumar HG,Kumar N,Gupta R .2023 .‐19 retreats and world recovers: A silver lining in the dark cloud. Health Care Sci, 2 : 264-85.
Ehsan F,Hanif F,Ishaq Q,Asim M,Yousaf M,Mansoor A .2024 .Prevalence of covid-19 breakthrough after vaccination and adverse effects of vaccines. Rawal Med J, 49 : 270-5.
Debata B,Patnaik P,Mishra A .2020 .‐19 pandemic! It's impact on people, economy, and environment. J Publ Affairs, 20 : e2372.
Standl E,Khunti K,Hansen TB,Schnell O. .2019 .The global epidemics of diabetes in the 21st century: Current situation and perspectives. Eur J Prev Cardiol, 26 : 7-14.
Wang D,Hu B,Hu C,Zhu F,Liu X,Zhang J .2020 .Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA, 323 : 1061-9.
Tsilingiris D,Vallianou NG,Karampela I,Christodoulatos GS,Papavasileiou G,Petropoulou D .2023 .Laboratory findings and biomarkers in long COVID: what do we know so far? Insights into epidemiology, pathogenesis, therapeutic perspectives, and challenges. Int J Mol Sci, 24 : 10458-62.
Zeng F,Huang Y,Guo Y,Yin M,Chen X,Xiao L .2020 .Association of inflammatory markers with the severity of COVID-19: A meta-analysis. Int J Infect Dis, 96 : 467-74.
Guo W,Li M,Dong Y,Zhou H,Zhang Z,Tian C .2020 .Diabetes is a risk factor for the progression. prognosis of COVID‐19. Diab Metabol Res Rev, 36 : e3319.
Alam MT,Mehdi A,Timsaal Y,Rehan M,Kumar A,Shaikh IS .2022 .The clinical course, biochemical markers, and clinical outcomes of COVID-19 positive patients from the third wave in Pakistan: A retrospective cohort study. Ann Med Surg, 77 : 103599.
Khurram M,Ali G,Awan UA,Afzal MS .2022 .COVID-19 and alarming dengue co-epidemics in the dilapidated healthcare system in Pakistan: Where to focus!. J Infect, 84 : 579-613.
Tahir S,Zaman S,Meraj L,Sheraz F,Dar SI,Shams N. .2021 .Predictors of Mortality of COVID-19 cases In Benazir Bhutto Hospital Rawalpindi. J Rawal Med Coll, 25 : 37-42.
Alqahtani FY,Aleanizy FS,Mohamed RA,Alanazi MS,Mohamed N,Alrasheed MM .2019 .Prevalence of comorbidities in cases of Middle East respiratory syndrome coronavirus: a retrospective study. Epidemiol Infect, 147 : e35.
Toori KU,Qureshi MA,Chaudhry A .2022 .Pre-morbidity, and COVID-19 disease outcomes in Pakistani population: A cross-sectional study. Pak J Med Sci, 38 : 287-90.
Alawadi F,Bashier A,Hussain AA,Al-Hashmi N,Bachet FA,Hassanein MM .2023 .Risk and predictors of severity and mortality in patients with type 2 diabetes and COVID19 in Dubai. World J Diab, 14 : 1259-64.
Albulescu R,Dima SO,Florea IR,Lixandru D,Serban AM,Aspritoiu VM .2020 .-19 and diabetes mellitus: Unraveling the hypotheses that worsen the prognosis. Exp Therap Med, 20 : 1-4.
Bornstein SR,Rubino F,Khunti K,Mingrone G,Hopkins D,Birkenfeld AL .2020 .Practical recommendations for the management of diabetes in patients with COVID-19. Lancet Diab Endocrinol, 8 : 546-50.
Moghaddam Tabrizi F,Rasmi Y,Hosseinzadeh E,Rezaei S,Balvardi M,Kouchari MR,J MR .2021 .Diabetes is associated with higher mortality and severity in hospitalized patients with COVID-19. , 20 : 444-53.
Mohammed Z,Mezher MN,Madfoon SM .2022 .Comparison of Serum Ferritin Levels between Diabetic Patients with COVID-19 and Non-diabetic Patients with COVID-19 Based on Age Groups and Gender. Iran J War Public Health, 14 : 165-70.
Malik SU,Chowdhury PA,Hakim A,Islam MS,Alam MJ,Azad AK .2022 .Blood biochemical parameters for assessment of COVID-19 in diabetic and non-diabetic subjects: a cross-sectional study. Int J Environ Health Res, 32 : 1344-58.
Salih WH .2023 .Elevated lactate dehydrogenase (LDH) and Creactive protein (CRP) level as a risk factor for critical. COVID-19. Rawal Med J, 48 : 565-9.
Wang Z,Du Z,Zhu F .2020 .Glycosylated hemoglobin is associated with systemic inflammation, hypercoagulability, and prognosis of COVID-19 patients. Diab Res Clin Pract, 164 : 108214.
Saha S,Al-Rifai RH,Saha S. .2021 .Diabetes prevalence and mortality in COVID-19 patients: a systematic review, meta‐analysis, and meta‐regression. J Diab Metabol Disord, 20 : 939-50.
Aziz F,Stöcher H,Bräuer A,Ciardi C,Clodi M,Fasching P .2022 .Biomarkers predictive for In-Hospital mortality in patients with diabetes Mellitus and Prediabetes hospitalized for COVID-19 in Austria: an analysis of COVID-. in Diabetes Registry. Viruses, 14 : 1285-9.
Gallo Marin B,Aghagoli G,Lavine K,Yang L,Siff EJ,Chiang SS .2021 .Predictors of COVID‐19 severity: a literature review. Rev Med Virol, 31 : 1-0.
0

Citations

0

Downloads

69

Views